Update on neuropsychiatric adverse events suspected to be associated with oseltamivir (Tamiflu®)

The Health Sciences Authority (HSA) would like to update healthcare professionals on the local neuropsychiatric adverse events reported which were suspected to be associated with oseltamivir (Tamiflu®). The Pharmacovigilance Branch (PVB) recently received 3 local reports describing disorientation, incoherent speech, hallucination and suicidal attempt suspected to be associated with oseltamivir. Although it is unclear if the causality of these events is directly due to oseltamivir, HSA advises healthcare professionals to be aware of these neuropsychiatric events and to advise caregivers of young patients of the potential risk of these events.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.